Question explored with the scientific record
Conversation so far
- 1 Are the chances of contracting MS as a result of the MRNA covid vaccine zero?
- 2 How about turbo cancers?
Answered on this page ↓
How about turbo cancers?
The evidence retrieved here cannot answer whether mRNA COVID-19 vaccines cause "turbo cancers" — none of the 16 records examines cancer incidence after vaccination.
The records cover myocarditis, shingles reactivation, anaphylaxis, and antiphospholipid syndrome [1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]. Three studies involve cancer patients, but they measure immune responses to vaccination, not whether vaccination causes cancer [1, 2, 3]. One shows shingles reactivation in a rectal cancer patient after mRNA vaccination [14], and another documents herpes zoster in 2.6% of actively treated cancer patients after a third dose [1]. These are reactivations of existing viruses, not new cancers.
The "turbo cancers" claim — that vaccination accelerates or causes aggressive malignancies — has no supporting evidence in this retrieval. No study here tracks cancer incidence in vaccinated versus unvaccinated people over time. That comparison is the only design that could answer your question, and it is absent from these records.
What the records do show is immune disruption: impaired T-cell counts correlating with shingles after vaccination [1], and vaccine-associated lymph node activation on PET scans in 31.4% of cancer patients [2]. Whether such disruption could promote malignancy is speculative. The mechanism is plausible in theory — chronic immune dysregulation can matter in cancer — but no retrieved study tests it.
My call: the evidence does not show mRNA vaccines cause turbo cancers, but it also contains no long-term cancer surveillance data to rule it out. Confidence: not clear — the question was never studied in the papers retrieved.
Sources used 15
-
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study
This prospective study investigates the incidence of herpes zoster in cancer patients following the third dose of the SARS-CoV-2 mRNA-BNT162b2 vaccine, revealing a cumulative incidence of 2.6% and highlighting the correlation between impaired T cell counts and herpes zoster occu…
DOI: 10.1007/s10238-023-01263-2 -
Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
This study investigates the correlation between vaccine-associated hypermetabolic lymphadenopathy (VAHL) observed in [18F]FDG PET-CT scans and humoral immunity in patients with hematologic malignancies following BNT162b2 mRNA Covid-19 vaccination.
DOI: 10.1007/s00259-021-05389-x -
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination
In infection-naïve solid tumor patients and age-matched controls, this study shows that mRNA COVID-19 vaccines elicit robust Fc effector antibody functions across SARS-CoV-2 variants despite inflammation-associated impairment of neutralization, and that a three-dose mRNA regimen…
DOI: 10.1038/s41541-025-01268-w -
Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system
Booster COVID-19 mRNA vaccination was associated with lower incidence and reporting risk of myocarditis/pericarditis compared with primary series, based on US VAERS and CDC COVID Data Tracker data from December 2020 to March 2022.
DOI: 10.3389/fimmu.2022.938322 -
Case of Covid Mrna Vaccine Linked Antiphospholipid Syndrome
This case report presents a 22-year-old male who developed antiphospholipid syndrome and a large pulmonary embolus following COVID mRNA vaccination, suggesting a potential autoimmune reaction linked to the vaccine.
DOI: 10.33140/ijdmd.07.01.07 -
Biphasic anaphylaxis after exposure to the first dose of Pfizer‐BioNTech COVID‐19 mRNA vaccine
A 30-year-old male with prior allergies developed an initial allergic reaction after the first Pfizer-BioNTech COVID-19 vaccine dose and a recurrent biphasic anaphylactic reaction on Day 3, treated with epinephrine and corticosteroids.
DOI: 10.1002/jmv.27109 -
Myocarditis With COVID-19 mRNA Vaccines
This narrative review characterizes myocarditis/pericarditis as a rare complication of COVID-19 mRNA vaccination, particularly in young males after the second dose, with a generally self-limited course and a favorable overall benefit-risk balance supporting universal vaccination.
DOI: 10.1161/circulationaha.121.056135 -
Case report: Five patients with myocarditis after mRNA COVID-19 vaccination
This case series of five adolescent males describes probable myocarditis after mRNA COVID-19 vaccination, with chest pain in all, ST elevation in all, troponin I increase in all but one, and full recovery.
DOI: 10.3389/fped.2022.977476 -
A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome
A 22-year-old healthy male developed antiphospholipid syndrome with a large pulmonary embolus, markedly elevated triple-positive antiphospholipid antibodies, and multisystem symptoms after his second dose of an mRNA COVID vaccine, with negative COVID testing, and improved on api…
DOI: 10.33140/bscr.02.01.13 -
Herpes Zoster Reactivation Following COVID-19 mRNA Vaccination in an Elderly Patient: A Case Report
An 82-year-old Indonesian woman developed herpes zoster reactivation 10 days after receiving the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, with PCR-confirmed VZV, and her lesions resolved with valacyclovir treatment.
DOI: 10.7454/jdvi.v9i1.1196 -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.
DOI: 10.1007/s12471-022-01677-9 -
Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination
Analysis of EU, US, and UK spontaneous reports found myocarditis/pericarditis after COVID-19 mRNA vaccines were reported at similar frequency in immunocompromised and overall populations, typically after dose 2 within 14 days, with broadened age/sex characteristics; events remai…
DOI: 10.1136/bmjopen-2021-060425 -
Delayed Hypersensitivity Reaction to Dermal Fillers Following mRNA COVID-19 Vaccination
A 59-year-old woman with prior hyaluronic acid dermal fillers developed recurrent facial swelling after Pfizer-BioNTech mRNA COVID-19 vaccination, and lisinopril was associated with a six-month symptom-free period.
DOI: 10.36472/msd.v11i8.1165 -
Reactivation of varicella-zoster virus following mRNA COVID-19 vaccination in a patient with moderately differentiated adenocarcinoma of rectum: A case report
A case report describes varicella-zoster virus reactivation after mRNA COVID-19 vaccination in a patient with moderately differentiated adenocarcinoma of the rectum.
DOI: 10.1177/2050313x221077737 -
Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report
Myocarditis after mRNA Covid-19 vaccines is rare, most common in younger men after the second dose, usually mild and self-limiting, with the benefit of vaccination outweighing the risk.
DOI: 10.1159/000522216